Slide 1: Investor Relations FY08 Conference Call
Investor Relations FY08 Conference Call December 1, 2008
Slide 2: Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 With the exception of historical information, the matters discussed in this presentation are forward looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ si
Slide 3: Introduction and Welcome
Introduction and Welcome • Introduction and Welcome • Agenda – Fourth Fiscal Quarter FY 2008 Summary – Entire FY 2008 Summary – Progress Review – Strategy Going Forward – Questions and Answers
Slide 4: Fourth Fiscal Quarter 2008 Summary
Fourth Fiscal Quarter 2008 Summary • Gross revenues = $1.84 MM (decrease of 17.9% from 4Q07) – Pharmaceutical software and services = $1.09 MM (down 25.4% from 4Q07) – Words+ subsidiary = $744,000 (down 3.6% from 4Q07) • SG&A = $995,000 (up 13.1% from 4Q07) • R&D Expense = $290,000 (up 54.4% from $1
Slide 5: Fourth Quarter FY08 Sales
Fourth Quarter FY08 Sales • Pharmaceutical software and services – Q4 revenues were down as a result of: • One order for $118,800 that was renewed early in Q3 • Nine companies that did not renew ($413,800): – 4 because of budget cuts » One of these may have money in 2009 ($112,500 last year) – 2 bec
Slide 6: Fiscal Year 2008 Summary
Fiscal Year 2008 Summary • Gross revenues = $8.97 MM (increase of 1.2% from FY07) – Pharmaceutical software and services = $6.06 MM (up 5.2% from FY07) – Words+ subsidiary = $2.91 MM (down 6.1% from FY07) • SG&A = $3.70 MM (41.2% of sales, up from 39.0% in FY07) • R&D Expense = $990,000 (up 21.5% fr
Slide 7: Fiscal Year 2008 Sales
Fiscal Year 2008 Sales • Net increase of 1.2% • Pharmaceutical software and services – Increase of 5.2% ($300,000) • Software licenses • Consulting services • Funded collaborations • Words+ – Decrease of 6.1% ($190,000) • Lower sales of “Freedom”, “TuffTalker Plus”, and MessageMate • Increase sales
Slide 8: Share Repurchase Agreement
Share Repurchase Agreement • Share repurchase agreement was approved by the board of directors: – Authorizes repurchase of up to $2.5 million in shares over one-year period beginning October 27, 2008 and ending October 26, 2009 – Subject to all applicable rules of the SEC and NASDAQ regarding stock
Slide 9: Progress During FY2008
Progress During FY2008 • ADMET Predictor/ADMET Modeler – Version 3.0 released in June • More than 50 new quantum charge-related descriptors added from the work we did under our Phase I SBIR project last year, and subsequent work funded internally • All existing property models retrained with the new
Slide 10: Progress - ClassPharmer and DDDPlus
Progress - - 2 • ClassPharmer – Version 4.5 released in June – Pair SAR (structure-activity relationship) feature allows rapid detection of small changes in molecular structure that result in large changes in properties – Full integration with ADMET Predictor • De novo molecule design capabilities h
Slide 11: Progress - GastroPlus
Progress - - 3 • GastroPlus – Version 6.0 released in June • Additional improvements to our new IVIVCPlus™ Module - important capability for generic and innovator companies • PKPlus™ Module - pharmacokinetics for multiple oral and iv doses • PDPlus™ Module - improved pharmacodynamic (response) model
Slide 12: Progress - Words+ subsidiary
Progress - - 4 • Words+ subsidiary – Third quarter set new record for revenues. Fourth quarter was down slightly. First two quarters were the major problem because of end-of-life issues with PDA used in previous product. New product release at the end of Q1 has now achieved excellent sales. – Major
Slide 13: Strategy Going Forward
Strategy Going Forward • Pharmaceutical software and services – Continue to seek and hire exceptional scientists to expand Life Sciences team – Greater investment in R&D for product enhancement and development of new products and services. Strategic planning meeting held in November, during which a
Slide 14: Summary
Summary • Company is financially strong with steadily growing cash position and no debt. Shareholder equity continues to grow at about 30%. • Growing, dedicated and extremely talented workforce • Marketing and sales efforts are being expanded in both businesses • We continue to be on the hunt for ac
Slide 15: Questions?
Questions? simulationsplus, inc, Of
Slide 16: Slide 16